WuXi's new facility in Philadelphia will manufacture CAR T-cell therapies and other cancer immunotherapies.
WuXi PharmaTech will soon begin construction of a new, 145,000-ft2 cGMP facility in Philadelphia, Pennsylvania for the manufacture of cell therapy products, the company announced on Mar. 12, 2015. This facility is designed for cell therapy products that contain viral vectors, such as chimeric antigen receptor T-cell (CAR T-cell) therapies, and will become WuXi's third cell-therapy manufacturing facility when it becomes operational by mid-2016.
The new facility will provide single-source contract development and cGMP manufacturing capabilities to support the rapidly growing cellular therapeutic industry's unique requirements, particularly the rapidly expanding demand for clinical studies and commercial supply, said the company in a press release. In the US, the new facility will expand upon WuXi's existing 16,000- ft2 cGMP cell therapy manufacturing facility and a 45,000- ft2 facility for the manufacturing of allogeneic and autologous cell-based therapeutics that is expected to be completed by mid-2015. These facilities will complement the company's current fully integrated facility for biological safety and lot-release testing in Philadelphia.
Source: WuXi PharmaTech
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.